Integer (ITGR) Q4 2025 earnings review
Solid 2025 Finish Overshadowed by Stagnant 2026 Outlook
Integer closed 2025 with robust Q4 results, delivering 23% Adjusted EPS growth and 5% revenue growth, driven by strength in Cardio & Vascular (+11%). However, the narrative is dominated by the 'air pocket' expected in 2026. Management's FY26 guidance confirms the fears raised in Q3: sales are projected to be flat (-1% to +1%) and Adjusted EPS growth will decelerate sharply to a midpoint of ~2%. While the company initiated a $50M accelerated share repurchase to support the stock, the divergence between the strong C&V segment and the contracting CRM & Neuromodulation segment signals near-term structural headwinds.
🐂 Bull Case
The C&V segment continues to outperform, growing 11.3% in Q4 (4.4% organic) and 16.6% for the full year. Strong demand in Electrophysiology and Neurovascular, coupled with acquisitions, provides a solid foundation that is masking weakness elsewhere.
Operating cash flow remained healthy at $196M for FY25. Management is deploying this capital actively, launching a $50M Accelerated Share Repurchase (ASR) program immediately, signaling confidence in the intrinsic value despite near-term headwinds.
🐻 Bear Case
Guidance for 2026 is anemic. Sales are guided -1% to +1% and Adjusted Operating Income is guided -5% to +1%. This represents a dramatic deceleration from the 13% operating income growth delivered in 2025, confirming that customer forecast cuts are a material drag.
The CRM & N segment has turned negative, shrinking 1.9% in Q4 (both reported and organic). Lower demand from emerging customers with PMA products—previously a growth driver—indicates potential adoption issues or inventory resets.
⚖️ Verdict: ⚪
Neutral. 2025 execution was excellent (EPS +21%), but the investment case is paused. 2026 is guided as a 'gap year' with zero growth. Until there is visibility on the 2027 rebound or stabilization in CRM/Neuromodulation, upside is capped by the lack of near-term catalysts.
Key Themes
CRM & Neuromodulation Reverses Course
A key negative development is the reversal in the CRM & Neuromodulation segment. After growing earlier in the year, Q4 sales fell 1.9% to $167M. Management cited 'lower demand from select emerging customers with PMA products.' This contradicts the prior narrative of emerging customers driving growth and raises concerns about the sell-through of these specific therapies.
Acquisitions Boosting Top Line
Inorganic growth remains a key lifeline. While organic growth in Q4 was only 2.0%, reported growth was 5.0%, lifted by the Precision Coating and VSi Parylene acquisitions. For the full year, C&V sales jumped 16.6%, significantly aided by M&A contribution (6.2% impact). As organic growth slows in 2026, integration of these assets becomes critical to holding the top line steady.
Profitability Resilience
Despite the slowing top line, Integer managed to expand margins in Q4. Adjusted Operating Income grew 10% on 5% sales growth, and Adjusted EBITDA margins held firm. However, the FY26 guidance suggests this leverage is exhausted, with Adjusted Operating Income forecast to be flat to down (-5% to +1%) next year.
Other Markets/Portable Medical Exit
The planned exit from Portable Medical continues to create a revenue headwind, driving the 'Other Markets' segment down 13% in Q4. While this is strategic and expected, it exacerbates the headline growth problem when the core CRM business is also shrinking.
Shareholder Returns via ASR
Management is using the balance sheet to manufacture EPS support. The company announced an accelerated share repurchase (ASR) of $50M. With leverage at 3.0x (within the 2.5x-3.5x target), there is room for this capital return, though it suggests a lack of immediate M&A targets or organic investment needs relative to cash generation.
Debt Levels Rising
Total debt increased by $195M in FY25 to $1.185B, primarily to fund acquisitions and the convertible notes offering. Interest expense remains a factor, and while the leverage ratio of 3.0x is manageable, the stalled EBITDA growth guided for 2026 (Adjusted EBITDA -3% to +3%) means deleveraging will pause.
Other KPIs
Stable/Growth. Up 11% reported and 4.4% organic. This remains the crown jewel, driven by Electrophysiology and Neurovascular demand. However, even this segment showed slight organic deceleration vs the full year organic rate of 10.2%.
Reversing. Down 1.9% reported. This segment has flipped from a stabilizer to a drag. The specific mention of weakness in 'emerging customers' is a red flag regarding the uptake of new therapies Integer was banking on.
Accelerating. Up 11% YoY, outpacing revenue growth of 5%. This indicates strong cost control and mix benefits, likely from the higher-margin C&V segment outperforming.
Guidance
Decelerating. The guidance implies -1% to +1% growth, a stark contrast to the 8% growth achieved in FY25. This confirms the 'growth gap' year previously hinted at in Q3.
Decelerating. Implicit growth of -2% to +6%. Compared to the 21% growth delivered in FY25, this confirms a stall in earnings momentum as operational leverage reverses.
Decelerating/Reversing. Growth of -5% to +1%. The midpoint implies a contraction in operating profit dollars, suggesting that cost inflation or fixed cost absorption on lower volumes will outweigh efficiency gains.
Key Questions
CRM & Neuro Demand Visibility
Q4 saw a 1.9% decline in CRM & Neuro due to 'emerging customers.' Is this a one-quarter inventory adjustment, or have the peak sales estimates for these PMA products been permanently reset?
Bridge to 2027 Growth
Management has previously guided to a return to above-market growth in 2027. Given the flat 2026 outlook, what specific product launches or program ramps provide the confidence for a sharp re-acceleration in 12 months?
Operating Leverage in a Flat Year
With sales guided flat and Operating Income guided down at the midpoint, what specific cost actions are being taken to protect margins, and is there risk to the 300bps of margin expansion achieved over the last few years?